New York, NY - July 23, 2012 - (Investorideas.com Newswire)
Investorideas.com, a leader in research for independent investors
presents an exclusive Q&A interview with Mr. William J. Caragol,
Chairman and Chief Executive Officer of
PositiveID Corporation (
OTCBB: PSID) discussing its M-BAND System for biothreat detection.
Q: Investorideas.com
Can you briefly explain to new investors how the M-BAND System
works and how it can be deployed in the BioWatch Generation 3 program?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Our Microfluidics-based Bioagent Networked Detector, called M-BAND,
was developed under contract for the Department of Homeland Security
(DHS), and is an early warning system designed to detect the intentional
release of aerosolized biological agents. It runs autonomously for up
to 30 days between service cycles, continuously analyzing air samples,
typically in high-traffic areas, for the detection of bacteria, viruses,
and toxins with results in as little as three hours. Results from
individual M-BAND instruments are reported via a secure wireless network
in real time to give an accurate and up to date status for instruments
in the field in aggregate. M-BAND was designed with a high level of
operational flexibility, and can be remotely set to detect for DNA-based
pathogens alone, with or without either RNA-based organisms or toxins,
or for all three types of pathogens simultaneously at remotely
programmable intervals.
Q: Investorideas.com
We understand the Department of Homeland Security wants to open
bidding before October for Generation 3 of the BioWatch program, now
estimated at $5.7 Billion. Where is PSID in the process?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We are currently awaiting the final RFP from the Department of
Homeland Security, which is expected to be released later this year. In
the meantime, we have made significant progress in our internal testing
of M-BAND, which detects five organisms on the Centers for Disease
Control Select Agents List, which is a requirement for BioWatch. Our
system is fully functional and, we believe, one of the only technologies
capable of addressing the requirements of the BioWatch procurement. We
are preparing for potential additional testing of our system as well.
Q: Investorideas.com
The other company bidding for the BioWatch program is Northrop Grumman (
NYSE:NOC); is this competitive against your technology or more synergistic?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We believe the M-BAND instrument offers a number of advantages over
similar products, including decreased consumable and operating costs, a
small footprint, a closed operating environment and significant
flexibility of operation. M-BAND has been designed and field tested
(both indoors and outdoors) to operate continuously for 30 days
unattended between scheduled services, which we believe to be higher
than competing technologies. It also operates using industry
gold-standard TaqMan® PCR (polymerase chain reaction) chemistry.
Q: Investorideas.com
Your Company was recently featured in a Bloomberg Businessweek.com
article discussing BioWatch; did that lend a new level of credibility
for your company being a small OTC listed stock?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We believe articles like the one published in Bloomberg
Businessweek shed light on the need for BioWatch Generation 3, and also
highlight and validate our technology and our company. Many people may
not have been previously aware of PositiveID or M-BAND, so it was very
significant for our company and technology to be featured alongside the
likes of Northrop Grumman. We have already received additional inquiries
and interest from large corporations around the world including for
possible partnership opportunities, as well as increased investor
interest.
Q: Investorideas.com
Are you targeting any other markets for
the M-BAND System globally?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Unfortunately, terrorism is not limited to the United States, so
M-BAND could be deployed in any location around the globe. In fact, the
system has been field tested in London.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer
of advanced technologies for diabetes management and rapid medical
testing, as well as airborne bio-threat detection systems for America's
homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or
MFS, is focused on the development of microfluidic systems for the
automated preparation of and performance of biological assays in order
to detect biological threats at high-value locations, as well as analyze
samples in a medical environment.
www.PositiveIDCorp.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector.
Sectors we cover include; cleantech and renewable energy stocks,
biotech stocks, mining and gold stocks, energy stocks, water, tech,
defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter
http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do
not make recommendations. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. We attempt
to research thoroughly, but we offer no guarantees as to the accuracy
of information presented. All Information relating to featured companies
is sourced from public documents and/ or the company and is not the
opinion of our web sites. This site is currently compensated by featured
companies, news submissions and online advertising. .More info:
www.InvestorIdeas.com/About/Disclaimer.asp
and disclosures: PositiveID Corporation compensates Investorideas.com
for news release publication, syndication on blogs and related sites and
email distribution and company profile: renewed July 2012 -3500 cash
and five hundred thousand shares for three months
http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com: 800 665 0411
Disclaimer/ Disclosure: Disclaimer: Our sites do not make
recommendations. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. We attempt to
research thoroughly, but we offer no guarantees as to the accuracy of
information presented. All Information relating to featured companies is
sourced from public documents and/ or the company and is not the
opinion of our web sites. This site is currently compensated by featured
companies, news submissions and online advertising. Disclosure:
PositiveID Corporation compensates Investorideas.com for news release
publication, syndication on blogs and related sites and email
distribution and company profile: renewed July 2012 -3500 cash and five
hundred thousand shares for three months . More info:
www.InvestorIdeas.com/About/Disclaimer.asp and disclosures:
http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system, or CNS, diseases. The company is
developing several product candidates in neurology and psychiatry to
address large market opportunities in epilepsy and ADHD including ADHD
patients with impulsive aggression. These product candidates include
Trokendi XR (extended-release topiramate), formerly known as SPN-538,
and SPN-804 (extended-release oxcarbazepine) for epilepsy, SPN-810 for
impulsive aggression in ADHD and SPN-812 for ADHD.
About Alnylam Pharmaceuticals